 | |
| Clinical data | |
|---|---|
| Other names | 07-PNET, fosnetupitant chloride hydrochloride |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C31H35F6N4O5P |
| Molar mass | 688.608 g·mol−1 |
Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant. It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.
In 2018, the U.S. Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron. The combination is also approved for medical use in the European Union and in Canada.
External links
- "Fosnetupitant". Drug Information Portal. U.S. National Library of Medicine.